While the opioid epidemic is one of the most urgent public health emergencies facing the U.S., new therapeutic approaches for treating the underlying substance use disorder have lagged far behind. | ...

Takeda has terminated a neuro partnership with Denali Therapeutics as the Japanese pharma undergoes a massive restructuring ...

AI powerhouse Anthropic is continuing its push into the healthcare arena with the acquisition of previously stealth AI ...

Zeto, which makes brainwave monitors for emergency rooms, received a third FDA clearance for an EEG device. The latest is ...

Newly uncloaked Stipple Bio is connecting the dots toward multiple early-stage clinical studies for its lead precision ...

The U.S. FDA and the U.K.’s Medicines and Healthcare products Regulatory Agency agreed to bolster their ongoing medical technology collaboration while also removing tariffs on British medicine exports ...

Ambrosia Biosciences is aiming to move the market beyond peptide-based obesity treatments and initiate a trial for its oral ...

Immunovant’s first-generation FcRn inhibitor flunked a pair of phase 3 eye disease trials, appearing to end the last hopes of ...

In the world of clinical trials, missing the primary endpoint of a pivotal trial typically spells real trouble for a drug ...

Liquid biopsy technologies, particularly circulating tumor DNA, or ctDNA, are changing how clinicians monitor hematologic ...

After the FDA placed two of its next-gen HIV drugs on clinical hold last June, Gilead Sciences has now terminated one of the ...

Have we passed the peak of biotech layoffs? It’s too early to say for certain—but an intriguing story is playing out in the ...